Anbio Biotechnology Class A Ordinary Shares carries no debt; cash flow comfortably covers obligations.

Anbio Biotechnology Class A Ordinary Shares's free cash flow has decreased -423.93% from $2.08M last year to $-6.74M, signaling decreasing performance

Anbio Biotechnology Class A Ordinary Shares's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Anbio Biotechnology Class A Ordinary Shares has insufficient data to evaluate this check.

Anbio Biotechnology Class A Ordinary Shares has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Anbio Biotechnology Class A Ordinary Shares earns at least as much interest as it pays. Interest obligations are fully covered.

Anbio Biotechnology Class A Ordinary Shares's profit margin has increased (148.68%) in the last year from 28.99% to 72.09%, signaling increasing performance

Anbio Biotechnology Class A Ordinary Shares's short-term assets of $30.24M exceed its short-term liabilities of $87.84K

Anbio Biotechnology Class A Ordinary Shares's return on assets of 28.07% is higher than the 5.00% threshold, indicating efficient asset utilization

Anbio Biotechnology Class A Ordinary Shares's return on equity of 27.49%, is higher than 15.00%, indicating good performance

Anbio Biotechnology Class A Ordinary Shares's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Anbio Biotechnology Class A Ordinary Shares had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings

Anbio Biotechnology Class A Ordinary Shares has negative free cash flow, indicating the company is burning cash rather than generating it

Anbio Biotechnology Class A Ordinary Shares has negative free cash flow, indicating cash burn

Anbio Biotechnology Class A Ordinary Shares's yearly earnings has increased 169.86% since last year from $2.37M to $6.40M, signaling increasing performance

Anbio Biotechnology Class A Ordinary Shares's yearly revenue has increased 19.22% since last year from $8.19M to $9.76M, signaling increasing performance

ROIC 25.46% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Anbio Biotechnology Class A Ordinary Shares's 3-year revenue CAGR of -28.39% is negative, indicating declining revenue over the past 3 years

Anbio Biotechnology Class A Ordinary Shares had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Anbio Biotechnology Class A Ordinary Shares had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity

Anbio Biotechnology Class A Ordinary Shares has insufficient data to evaluate this check.

Anbio Biotechnology Class A Ordinary Shares has an earnings yield of 2.03%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Anbio Biotechnology Class A Ordinary Shares is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Anbio Biotechnology Class A Ordinary Shares has an EV/EBITDA ratio of 71.02x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Anbio Biotechnology Class A Ordinary Shares has insufficient data to evaluate this check.

Anbio Biotechnology Class A Ordinary Shares has a PEG-ratio under 1 which is considered undervalued

Anbio Biotechnology Class A Ordinary Shares has a price-to-book ratio of 13.84x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Anbio Biotechnology Class A Ordinary Shares has a price-to-sales ratio of 35.45x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue